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of standardization, were among the first to initiate new
pharmacoeconomic and pharmacoepidemiological devel-
opments. At the third stage, the establishment of a stan-
dardization service is envisaged. In addition to regulatory
documentation development proper, the service will be en-
gaged in putting these standards and specifications into
practice and in analyzing the results on the introduction of
specific regulatory documents. The I. M. Sechenov Moscow
Medical Academy (its Laboratory of Outcomes and Stan-
dardization Research Problems) has been appointed the
central research institution to deal with standardization
problems. It is entrusted with the duties of a coordinator of
research developments, an expert in the existing documents
and a developer of a standardizing base (now lacking). In
1999, a conference is to be held and a scientific journal cov-
ering standardization problems will begin publication.
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This workshop is intended for individuals with a basic un-
derstanding of the concepts and terminology of economic
evaluation of healthcare who want to discuss applied stan-
dardization methodologies. Several software tools are
available to assist in the development of pharmacoeco-
nomic models. However, the lack of a standardized set of
rules to present economic evaluation results may limit the
comparability of studies carried out by different analysts.
The objective of this session is to define a set of standard-
ized procedures to improve the comparability of results of
economic evaluation studies by means of user-friendly
computer software for Reporting Economic Evaluation
Results (the REER software). Two different prototypes
will be presented: an application aimed at presenting eco-
nomic evaluation results; and a health costs database
(HCD). The main program (REER) is divided into three
basic modules: 1) definition of options (treatment/interven-
tion comparators, subjects); 2) data inputs (resources, unit
costs, health outcomes, discounting and sensitivity analy-
sis); and 3) outputs (differences in costs and effects, domi-
nance analysis, incremental analysis, and sensitivity analy-
sis). A prototype version of the REER software will be
presented by means of two published pharmacoeconomic
analyses. The Health Costs Database Software (HCDS) en-
ables the collection, categorization, and storage of unit
cost data to be used in different types of studies (e.g., cost
analysis, economic evaluation). The database, which sim-
plifies the retrieval of average and actualized cost figures,
makes rapidly available updated unit cost data which can
be used directly (e.g., within the REER software), as a first
calculation, or can be contrasted with later cost estima-
tions. Problems with obtaining standardized results of eco-
nomic evaluation studies and the usefulness of programs
such as the REER software will be examined, and future
development of complete and fully operational software
tools will be discussed.
TRACK 3: QUALITY OF LIFE ASSESSMENT
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The DARTS database is a validated, population-based reg-
ister of 9,000 patients with diabetes in the population of
Tayside, Scotland, compiled by the record-linkage of inde-
pendent datasets. These include diabetes clinic records,
hospital activity data, biochemistry results, and a database
of dispensed prescriptions. The database can be used for
epidemiological, outcomes, and health services research.
Diabetes is a disease with high morbidity and mortality,
for which treatments are onerous and time-consuming.
Thus the nonclinical or psychological dimension should
not be ignored, and so the incorporation of quality of life
measures into DARTS has been proposed. A wide range of
disease-specific and generic measures that tap into many
different facets of quality of life have already been used in
diabetes. The challenge is to identify a valid and reliable
package of measures that could be practical for the dia-
betic patients of Tayside. In this workshop, the approach
adopted to identify such a package for routine use in
DARTS will be described and discussed. It will include a
critical review of quality of life measures that have already
been used in diabetic patients, the results of a survey of di-
abetic patients and diabetic health professionals to identify
those aspects of quality of life deemed to be particularly
relevant to diabetes, and a discussion of the validation of
the measures chosen in a pilot group of patients. The
workshop would thus be of interest to researchers working
with quality of life outcome measures, and/or to those in-
volved in the development and application of disease-
specific databases.
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The measurement of a product’s intrinsic value has become
an essential part of a new technology’s reimbursement and
marketing strategy. The key tactics in the evaluation of a
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product’s value are the economic and humanistic conse-
quences of the new therapy relative to the gold standard.
However, in many circumstances, the patient is unable to
provide an accurate assessment of healthcare resources
consumed or their quality of life and functional status. Re-
searchers have opted for the use of proxies in these in-
stances, under the presumption that a larger sample size in-
creases the power to detect meaningful differences. This
presumption, however, neglects the inaccuracies inherent
in proxy reporting and thus may inhibit the reliability of
the estimates obtained. This workshop will review and
evaluate the use of proxy respondents in the collection of
resource utilization and quality of life data. A critical ex-
amination will be given to their potential influence on study
results. Suggestions for overcoming these issues will also be
presented and discussed. This session is directed at individ-
uals in pharmaceutical firms, contract research organiza-
tions (CROs), and consultant companies responsible for
the design and conduct of pharmacoeconomic evaluations.
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Assessing the impact of disease and the effect of treat-
ment on patient quality of life (QoL) has become of ma-
jor importance both to the pharmaceutical industry and
the medical profession. The last 20 years have seen the
development of a large number of QoL questionnaires,
increasingly being used in clinical trials, with a growing
emphasis on multinational applications. As a result, there
is a continually expanding need for cross-nationally and
cross-culturally valid, reliable and responsive QoL instru-
ments. This course will provide key information and op-
erational solutions to implement health status and QoL
measures in clinical trials. The content of the course will
cover definitions of health status and QoL; types of in-
struments used, including their strengths and weaknesses;
identification of concepts to be measured; and selection
of relevant instruments. The second part of the course
will focus on strategy for instrument development, lin-
guistic validation and psychometric validation, as well as
interpretation guidelines. Participants will acquire a com-
mon baseline understanding of health and QoL evalua-
tions, allowing them to become actively involved in de-
velopment of optimal programs for clinical development
and marketing purposes.
TRACK 4: STUDY METHODS
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An important element in judging the worthiness of a new
drug’s effects is the translation of randomized trial results
to actual clinical practice. A key input is the risk experi-
enced by routinely managed patients. The risk rate is im-
portant, because the relative risk reduction typically esti-
mated in trials only gains meaning when it is applied to
such a reference risk. While the relative risk reduction is
widely believed to be generalizable, the reference risk is not.
In this workshop, an ongoing study, CAPRA (CAPRIE Ac-
tual Practice Rates Analysis) will be used as a case study—
along with other published reports—to examine why con-
sidering information beyond that obtained in a clinical trial
can be critical in assessing the value of a new therapy. The
major reasons practice may diverge from trials, along with
evidence of this fact, will be introduced. The methods for
extending trial results to clinical practice will be demon-
strated and discussed, along with alternative approaches to
estimating actual practice results from clinical trial experi-
ence. The focus will be on the use of epidemiologic studies
and databases such as that from Saskatchewan Health. De-
tails of this analysis of records for 12,931 patients used to
estimate the risk of first subsequent ischemic events (MI, is-
chemic stroke, vascular death) in actual practice will be
shown. The magnitude of the distortion, with special refer-
ence to numbers needed to treat, and the implications for
cost-effectiveness analysis will be presented. All available
information and methods ought to be employed when con-
sidering a new therapy, as it is insufficient to evaluate a new
therapy based on trial results alone.
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Most pharmacoeconomic studies present estimates of the
impact of new treatments on expected lifetime costs and
health outcomes for typical individuals with a given dis-
ease. However, national or local healthcare decision-
makers also need to know what impact the new treat-
ment will have on their annual budgets and on annual
health outcomes for their patient populations. In this
workshop, a method for estimating the population im-
pacts of new treatments is presented. How information
about the impact of a new treatment on individual pa-
tients can be combined with information about the num-
ber and type of patients in the patient population to esti-
